Adults with pre-diabetes and obesity or overweight treated with tirzepatide had sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Palatin completes study enrolment of bremelanotide plus tirzepatide to treat obesity
Tirzepatide results in greater weight loss in women than men
Large-scale population analysis confirms safety profile of tirzepatide
Journal Watch 10/7/2024
Patients receiving tirzepatide were significantly more likely to achieve clinically meaningful weight loss compared with those treated receiving semaglutide
Tirzepatide associated with a potential targeted effect on visceral fat and liver fat
Semaglutide and tirzepatide decrease cravings and reduce alcohol consumption
Journal Watch 01/11/2023
Journal Watch 07/06/2023
